Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Following last summer’s FDA rejection of MDMA-assisted therapy for PTSD, veteran-led advocacy groups Healing Breakthrough and Heroic Hearts Project are uniting. In this exclusive interview, Jesse Gould and Juliana Mercer say the fight is far from over—and that healing shouldn’t require a passport.
Psychedelics Namechecked in Trump Cabinet Meeting • Noma Therapy Raises $4.25M, Aims to Disrupt At-Home Ketamine With Insurance-Friendly Approach • Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet • and more…
Explore or interactive database of psychedelic patent activity in March and April 2025 via our new interface. We also cover a handful of related headlines: from Lykos Therapeutics’ latest MDMA-related patent woes to a patent application-assisted peek under the hood of Seaport Therapeutics’ 2-Bromo-LSD program.
The UK’s seventh biennial international conference on psychedelic consciousness welcomed researchers, clinicians and delegates to the University of Exeter from 17–19 April. In this first instalment, we dive into ketamine’s path into public healthcare, efficient and ethical trial designs, overlooked risks in the underground psychedelic scene, and whether new modalities of care can avoid repeating psychiatry’s historic mistakes.
Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona • Make-or-Break Moment Looms for Compass Pathways • Makary Outlines Vision for Faster Drug Approvals • RFK Jr. Details Teenage Acid Trip That Preceded Years of Addiction • Enthea Ventures into Oregon’s Psilocybin Services • A Neuroimmune Theory of Psychedelic Action? • Pilot Study Explores Psilocybin for Mood Dysfunction in Parkinson’s Disease • and more…
Q1 2025 saw roughly $350M flow into the psychedelics industry, the majority of which accrued to a trio of publicly-trader drug developers. Explore key trends, private vs. public dynamics, and what Compass Pathways’ upcoming Phase 3 results could mean for the remainder of 2025.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
This is an archived version of our Psychedelic News Feed, from December 11 2023 – January 7 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
